Enterprise Value

177.6M

Cash

88.43M

Avg Qtr Burn

-18.34M

Short % of Float

11.59%

Insider Ownership

10.07%

Institutional Own.

62.43%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

Phase 2

Initiation

PRGN-2012 AdenoVerse™ Details
Recurrent respiratory papillomatosis

Phase 1/2

Data readout

PRGN-3005 UltraCAR-T® Details
Ovarian cancer, Cancer

Phase 1b

Data readout

PRGN-3006 UltraCAR-T® Details
Cancer, Myelodysplastic syndrome, Acute myeloid leukemia

Phase 1b

Data readout

PRGN-3007 UltraCAR-T® Details
Cancer, Solid tumor/s, Blood cancer

Phase 1

Data readout

AG019 ActoBiotics™ Details
Type 1 diabetes, Diabetes

Failed

Discontinued